N.Y.--(BUSINESS WIRE)--Feb. 17, 2005--
Technologies, Inc. (OTCBB:BIPH), a developer of next-generation
biomedical technology, announced that it has been named
to receive the Nano Science and Technology Institute's
(NSTI) Early Stage Company Award, to be presented at
its February 23-25 conference in Tokyo, Japan.
Company Invited to Tokyo ICS-Nanotech 2005 Conference
to Accept Award and Deliver Address on Biophan's Nano-based
Advances and Solutions
The ICS-NSTI's Early
Stage Company Award recognizes superior innovation
and achievement by development-stage companies providing
leadership in the science and business of nanotechnology.
NSTI is a respected organization that works to promote
education, research and business development in nanoscience
and related fields. Biophan has developed a rich portfolio
of patents and intellectual property that provide
a range of solutions to important problems in healthcare,
among them, the application of nanotechnology to improve
the safety and effectiveness of Magnetic Resonance
Imaging (MRI), one of medicine's most important diagnostic
that Biophan's continuing advances in nanotechnology
have been recognized by the Nano Science and Technology
Institute," said Michael Weiner, Biophan's CEO.
"The award is an important validation of Biophan's
research and development in applications of nanotechnology
that have the potential to enable substantial advances
in healthcare and the life sciences, and to incorporate
nanotechnology into the multi-billion-dollar worldwide
markets in medical devices, drug delivery, power systems,
and other sectors. Our company is built on the development
of intellectual property from the laboratory to the
marketplace, and the ISC-NSTI Early Stage Company
Award helps demonstrate our contributions to the nanoscience
The ICS-NSTI Early
Stage Company Award includes a modest cash award and
an invitation for Biophan's representative to address
attendees at the Tokyo conference, to present the
Company's advanced nanotechnology-based biomedical
solutions and research. Approximately 20,000 nanoscience
research and business professionals are expected to
attend the conference.
In addition, Biophan
has been accepted by NSTI into its Nanotech Ventures
program commencing at the Nanotech 2005 Conference
and Trade Show on May 8-12, in Anaheim, California.
Biophan will make a presentation at that gathering,
as part of the organization's Nanotech 2005 Early
Stage Company Review, a forum designed to allow companies
to showcase their technologies and solutions.
About the Nano Science
and Technology Institute
The Nano Science and
Technology Institute (NSTI) is chartered with the
promotion and integration of nano and other advanced
technologies through education, technology and business
development. NSTI accomplishes this mission through
its offerings of consulting services, continuing education
programs, scientific and business publishing and community
outreach. NSTI produces the annual Nanotech conference
and trade show, the most comprehensive international
nanotechnology convention in the world. NSTI also
produces BioNano and Stem Cell Strategies conferences.
NSTI was founded in 1997 as a result of the merger
between various scientific societies, and is headquartered
in Cambridge, Mass., with additional offices in California
and Switzerland. For more information about NSTI,
About Biophan Technologies
Biophan develops and
markets cutting-edge technologies designed to make
biomedical devices safe and compatible with the magnetic
resonance imaging (MRI) environment. The Company develops
enabling technologies for implanted medical systems
such as pacemakers and interventional surgical devices
such as catheters, guidewires, stents, and other implants
to allow them to be safely and effectively imaged
under MRI. The technology is also being used to create
MRI contrast agents, and has expanded to include other
applications, such as drug delivery and power systems
derived from body heat. Four Biophan technologies
include advances in nanotechnology and thin-film coatings.
Committed to growth through innovation and developmental
leadership, Biophan and its licensors now hold a total
of 104 U.S. patents, licenses, or applications. This
total includes 30 issued U.S. patents, 6 recently-allowed
applications that will issue as patents in the near
future, and 68 pending applications at various stages
of examination at the U.S. Patent and Trademark Office.
The patents cover areas including nanotechnology (nanomagnetic
particle coatings), radio frequency filters, polymer
composites, thermoelectric materials for batteries
generating power from body heat, and photonics. Biophan
has joint development arrangements with Boston Scientific
(NYSE: BSX - News) and NASA's Ames Center for Nanotechnology.
Biophan's goal is to make all biomedical devices capable
of safely and successfully working with MRI, and delivering
other technologies which will improve quality of life.
For more information, please visit www.biophan.com.
To view the Company's Investor Fact Sheet, or ongoing
installments of "Biophan 101" informational
videos about aspects of the Company's next-generation
biomedical solutions, visit http://www.trilogy-capital.com/tcp/html/biophan.htm.
Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
Jennifer Gould, 212-843-8037